heterogeneity – Page 3 – Communicable Diseases Research

Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study

Article

Published on 2022-10-262022-11-15
Journal: mBio [Category] COVID19(2023년), SARS, 진단,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome addition adopted Adverse adverse event AEs amplification antibodies CCP Clinical outcome competing Concentration conducted convalescent convalescent plasma coronavirus COVID-19 death defined donors dose response Effectiveness eligible evaluate evaluated event Fisher Gray hazard ratio heterogeneity high-risk population hospital hospital discharge immunology Inconclusive Infection Lower Mortality NAb Neutralizing antibodies neutralizing antibody observational study occurred participant Patient positive primary clinical outcome randomized control trial receiving Registered Research Respiratory Support Result risk SAEs SARS-CoV-2 SARS-CoV-2 nucleic acid screened Secondary outcomes severe COVID-19 Standard of care Support Symptom therapeutic therapy time titer Treatment
[DOI] 10.1128/mbio.01751-22 PMC 바로가기

Comparable diagnostic accuracy of SARS-CoV-2 Spike RBD and N-specific IgG tests to determine pre-vaccination nation-wide baseline seroprevalence in Mexico

Article

Published on 2022-10-262022-11-15
Journal: Scientific Reports [Category] COVID19(2023년), SARS, 진단, 치료기술,

Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants

Article

Published on 2022-10-262022-11-15
Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] 95% CI appear applied approach Blood booster booster vaccination Booster vaccine Cellulose country COVID COVID-19 pandemic decrease evaluate evaluated heterogeneity immune response Immunity immunological protection increase in indicated individual individual level induce median MONITOR NAb Neutralization antibody Neutralizing Neutralizing antibodies neutralizing antibody omicron Omicron variant pandemic POC point of care point-of-care point-of-care test population level predominant Protective Rapid regimen reported responses against SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants shown stick switching vaccination variant variants of concern variants of SARS-CoV-2 virus neutralization test VoC VOCs waning immunity wild-type
[DOI] 10.1128/spectrum.02257-22 PMC 바로가기

Does vitamin D supplementation reduce COVID-19 severity?: a systematic review

Article

Published on 2022-10-252022-11-16
Journal: QJM: An International Journal of Medicine [Category] meta-analysis,

The safety of esophageal cancer surgery during COVID-19

Article

Published on 2022-10-142022-11-16
Journal: Medicine [Category] meta-analysis,

Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study

Article

Published on 2022-10-142022-11-15
Journal: eLife [Category] COVID19(2023년), SARS, 바이오마커, 진단,

[키워드] Abuse Accelerator Antibody Response association Biomarker BNT162b2 characterized clinical trial coronavirus Course COVID-19 COVID-19 patients Critical CXCL10 cytokine dataset develop Disease progression Donor drug early IFN signaling Eiger BioPharmaceuticals enrolled Enrollment heterogeneity Host identify immune immune marker immune response immune signature immunological immunology independent individual Infection Infectious disease Inflammation machine-learning majority marker MCP-3 MCP1 Medicine memory Mild mRNA vaccination natural infection outcome Outpatient outpatients Patient Pfizer-BioNTech plasma plasma protein Post-infection predict Predictive Predictive modeling proteomics provided receiving RIG-I SARS-CoV-2 SARS-CoV-2-infected patients severe symptoms Stanford Stanford University subsequent systems immunology T cell T cell memory the antibody response trajectory transcriptomics Vaccine viral shedding Virological viruses with COVID-19
[DOI] 10.7554/eLife.77943 PMC 바로가기

Genetic variants determine intrafamilial variability of SARS-CoV-2 clinical outcomes in 19 Italian families

Article

Published on 2022-10-132022-11-15
Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, 치료기술,

The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination

Article

Published on 2022-10-112022-11-15
Journal: Immunity [Category] COVID19(2023년), SARS, 진단,

An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients

Article

Published on 2022-10-052022-11-16
Journal: eLife [Category] COVID19(2023년), SARS, 변종,

[키워드] adjusted Analysis Appendix approach assumption available data Calabria carrier caused changes in characterisation clinical Clinical outcome Clinical research clinical study collected Commonwealth confidence interval confounders COVID-19 dataset DAVID development Donor emergence Epidemiology European European Commission fatality Foreign foundation Frequency funding global health Google.org group heterogeneity Horizon hospital hospitalised hospitalised patient Imperial College London include infecting Infection Infectious disease International IRCCS ISARIC Italian Joshua less Logistic regression lower mortality Medical Research Council Medicine Melinda Gate Microbiology Ministry of Health network NIHR NIHR HPRU Odds ratio office omicron opportunity outcome Oxford Patient PHE protection Public Health England Rapid relative frequencies reported symptom Research respiratory response responsible Rockefeller Foundation SARS-CoV-2 variant School Semple sensitivity analysis Sriniva study population subset Support supported Symptoms union unit University of Liverpool University of Oxford variant variants viral genomic information viruses with COVID-19
[DOI] 10.7554/eLife.80556 PMC 바로가기

MIS-C: A COVID-19-as sociated condition between hypoimmunity and hyperimmunity

Article

Published on 2022-10-032022-11-15
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 바이오마커, 변종,

[키워드] activated Activation acute phase Admission Analysis ATM Autoimmune Autoimmune disease Autoimmune diseases autoimmune pathogenesis autoinflammatory disease Autoinflammatory diseases B cell cellular Characteristics children clearance complication of COVID-19 contribute Critical cytokine response Cytokine storm Cytokines Cytometry demonstrated develop diagnostic biomarker DOCK8 event FCN3 Flow flow cytometry Genetic Genetic variant healthy control help heterogeneity Hospital admission identified variant IFN IFN-α IFN-β IFN-γ IFNγ IL-10 IL-12p70 IL-17A IL-6 immune dysregulation immunodeficiency immunological induce Inflammatory inflammatory pathway involved knowledge lymphocyte lymphopenia management MCM4 MIS-C MOST multisystemic mutated NCF1 NGS NOD2 organ Pathogenesis pathway Patient patients Population PRF1 reduction serum serum cytokine significant increase syndrome Th1 the disease therapeutic Therapies tissue damage TNF Type variant was increased
[DOI] 10.3389/fimmu.2022.985433 PMC 바로가기